专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

51. 发明专利

DE60138955D1 XANTHIN-PHOSPHODIESTERAS-V-INHIBITOREN 未知
公开(公告)号：DE60138955D1
公开(公告)日：2009-07-23
申请号：DE60138955
申请日：2001-09-17
申请人： SCHERING CORP
发明人： CHACKALAMANNIL SAMUEL , WANG YUGUANG , BOYLE CRAIG D , STAMFORD ANDREW W
IPC分类号： C07D473/04 , A61K31/522 , A61K45/00 , A61P1/00 , A61P3/10 , A61P9/00 , A61P9/10 , A61P9/12 , A61P13/00 , A61P13/12 , A61P15/00 , A61P27/06 , A61P35/00 , A61P37/06 , A61P37/08 , A61P43/00 , C07D473/02 , C07D473/06 , C07D473/08 , C07F7/18
摘要： A xanthine phosphodiesterase V inhibitor having the formula (I), with the variables defined herein, which is especially useful for treating male (erectile) and female sexual dysfunction and other physiological disorders: For example, a representative compound of the invention is:

52. 发明专利

MX2009003761A DERIVADOS BICICLICOS Y TRICICLICOS COMO ANTAGONISTAS DEL RECEPTOR DE TROMBINA. 未知
公开(公告)号：MX2009003761A
公开(公告)日：2009-06-30
申请号：MX2009003761
申请日：2007-10-02
申请人： SCHERING CORP
发明人： XIA YAN , CHACKALAMANNIL SAMUEL , CHELLIAH MARIAPPAN V , WANG YUGUGUANG
IPC分类号： C07D401/06 , C07D417/06
摘要： Los tricíclicos heterocíclicos-sustituidos de la fórmula (I): (ver fórmula (I)) o una sal o solvato farmacéuticamente aceptable de dicho compuesto, isómero o mezcla racémica, en donde representa un enlace doble opcional, la línea punteada es opcionalmente un enlace o no es un enlace, dando como resultado un enlace doble o un enlace sencillo, según lo permita el requerimiento de valencia y en donde E, A, G, M Het, B, X, R3, R10, R11, R32 y R33 son como se definen en la presente y los sustituyentes restantes son como se definen en la especificación, así como composiciones farmacéuticas que los contienen y un método para el tratamiento de enfermedades asociadas con trombosis, aterosclerosis, restenosis, hipertensión, angina de pecho, arritmia, paro cardíaco, cáncer, con la administración de dichos compuestos; también se reclama la terapia de combinación con otros agentes cardiovasculares.

53. 发明专利

AT433454T 未知
公开(公告)号：AT433454T
公开(公告)日：2009-06-15
申请号：AT05854388
申请日：2005-12-19
申请人： SCHERING CORP
发明人： CLASBY MARTIN , CHACKALAMANNIL SAMUEL , NEUSTADT BERNARD , GAO XIAOBANG
IPC分类号： C07D487/04
摘要： Compounds having the structural formula I are disclosed, wherein A is alkylene, or optionally substituted arylene, cycloalkylene or heteroaryldiyl; X is —C(O)— or —S(O)2—; R1 is alkyl or cycloalkyl; R2 is hydrogen, halo or —CN; R3 is hydrogen or alkyl; R4 is hydrogen, alkyl, alkoxy, hydroxyalkyl, aminoalkyl-, cycloalkyl, heterocycloalkyl, heterocycloalkyl substituted by alkyl, optionally substituted arylalkyl or optionally substituted heteroarylalkyl; or R3 and R4, form an optionally substituted 5-7 membered ring, said ring optionally comprising an additional heteroatom ring member; R7 is alkyl, optionally substituted phenyl, optionally substituted heteroaryl, cycloalkyl, halo, morpholinyl, optionally substituted piperazinyl, or optionally substituted azacycloalkyl. Also disclosed is the use of the compounds in the treatment of Parkinson's disease, alone or in combination with other agents for treating Parkinson's disease, pharmaceutical compositions comprising them and kits comprising the components of the combinations.

55. 发明专利

HK1119681A1 7-[2-[4-(6-FLUORO-3-METHYL-1,2-BENZISOXAZOL-5-YL)-1-PIPERAZINYL]ETHYL]-2-(1-PROPYNYL)-7H-PYRAZOLO-[4,3-E]-[1,2,4]-TRIAZOLO-[1,5-C]-PYRIMIDIN-5 AMINE 未知
公开(公告)号：HK1119681A1
公开(公告)日：2009-03-13
申请号：HK08111733
申请日：2008-10-24
申请人： SCHERING CORP
发明人： BOYLE CRAIG D , CHACKALAMANNIL SAMUEL , SHAH UNMESH G , LACHOWICZ JEAN E
IPC分类号： A61K20060101 , A61P20060101 , C07D20060101
摘要： The compound having the structural formula I or a pharmaceutically acceptable salt thereof, is disclosed, as well as its use in the treatment of central nervous system diseases, in particular Parkinson's disease, Extra Pyramidal Syndrome, restless legs syndrome and attention deficit hyperactivity disorder, pharmaceutical compositions comprising it, and combinations with other agents.

56. 发明专利

AU2005236059B2 Pyrazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]-pyrimidine adenosine A2a receptor antagonists 未知
公开(公告)号：AU2005236059B2
公开(公告)日：2009-01-15
申请号：AU2005236059
申请日：2005-04-19
申请人： SCHERING CORP
发明人： BOYLE CRAIG D , NEUSTADT BERNARD R , STAMFORD ANDREW , HARRIS JOEL M , SHAH UNMESH G , CHACKALAMANNIL SAMUEL , HAO JINSONG , LIU HONG
IPC分类号： C07D487/14 , A61K31/519
摘要： Compounds having the structural formula I or a pharmaceutically acceptable salt thereof, wherein R is optionally substituted phenyl, furanyl, thienyl, pyridyl, pyridyl N-oxide, oxazolyl or pyrrolyl, or cycloalkenyl R1, R2, R3, R4 and R5 are H, alkyl or alkoxyalkyl; and Z is optionally substituted aryl or heteroaryl are disclosed. Also disclosed is the use of compounds of formula I in the treatment of central nervous system diseases, in particular Parkinson's disease, alone or in combination with other agents for treating Parkinson's disease, and pharmaceutical compositions comprising them.

57. 发明专利

AT413388T 未知
公开(公告)号：AT413388T
公开(公告)日：2008-11-15
申请号：AT03726436
申请日：2003-04-24
申请人： SCHERING CORP
发明人： BOYLE CRAIG , GREENLEE WILLIAM , CHACKALAMANNIL SAMUEL
IPC分类号： C07D221/20 , A61K31/4523 , A61P25/00 , C07D211/96

58. 发明专利

DE602005009355D1 未知
公开(公告)号：DE602005009355D1
公开(公告)日：2008-10-09
申请号：DE602005009355
申请日：2005-05-25
申请人： SCHERING CORP
发明人： CHELLIAH MARIAPPAN V , CHACKALAMANNIL SAMUEL , XIA YAN , CLASBY MARTIN C , GREENLEE WILLIAM J , WANG YUGUANG , VELTRI ENRICO P , WU WENXUE , GRAZIANO MICHAEL P , KOSOGLOU TEDDY , CHINTALA MADHU
IPC分类号： C07D405/08 , A61K31/443 , A61K31/4433 , A61P9/00 , A61P11/00 , A61P25/28 , C07D405/06 , C07D493/04

59. 发明专利

ECSP088628A MODULADORES DE RECEPTORES CANNABINOIDES 未知
公开(公告)号：ECSP088628A
公开(公告)日：2008-08-29
申请号：ECSP088628
申请日：2008-08-16
申请人： SCHERING CORP
发明人： CHELLIAH MARIAPPAN V , GREENLEE WILLIAM J , CHACKALAMANNIL SAMUEL , EAGEN KEITH A , WANG YUGUANG , XIA YAN , CLASBY MARTIN C , SCOTT JACK D
IPC分类号： C07D209/44 , C07D401/12 , C07D405/12
摘要： Un compuesto que posee la estructura general de la Fórmula (I): (I)o una sal, solvato, o éster del mismo aceptable para uso farmacéutico, es útil para tratar enfermedades, trastornos o afecciones tales como obesidad, trastornos metabólicos, adicción, enfermedades del sistema nervioso central, trastornos cardiovasculares, trastornos respiratorios y trastornos gastrointestinales.

60. 发明专利

NO325690B1 未知
公开(公告)号：NO325690B1
公开(公告)日：2008-07-07
申请号：NO20025965
申请日：2002-12-12
申请人： SCHERING CORP
发明人： CHACKALAMANNIL SAMUEL , XIA YAN , CHELLIAH MARIAPPAN
IPC分类号： C07D405/06 , A61K31/443 , A61K31/4436 , A61K31/4439 , A61K31/444 , A61K31/497 , A61P3/10 , A61P7/02 , A61P9/00 , A61P9/04 , A61P9/06 , A61P9/10 , A61P9/12 , A61P11/00 , A61P11/06 , A61P13/12 , A61P19/02 , A61P19/10 , A61P25/00 , A61P29/00 , A61P35/00 , A61P43/00 , C07D405/14 , C07D409/14 , C07D413/14 , C07D417/14 , C07D521/00
摘要： Heterocyclic-substituted compounds of formula (I) or a pharmaceutically acceptable salt thereof, are disclosed, wherein: Z is - (CH2)n-; (a); (b), wherein R 10 is absent; or, (c) wherein R 3 is absent; the single dotted line represents an optional double bond; the double dotted line represents an optional single bond; n is 0-2; Het is an optionally substituted mono-, bi- or tri-cyclic heteroaromatic group; B is -(CH 2 ) n3 -. wherein n 3 is 0-5, -CH 2 -O-, -CH 2 S-, -CH 2 -NR 6 -, -C(O)NR 6 -. -NR 6 C(O)-, (d), optionally substituted alkenyl or optionally substituted alkynyl; X is -O- or -NR 6 - when the double dotted line represents a single bond, or X is H, -OH or -NHR 20 when the bond is absent; Y is =O, =S, (H, H), (H, OH) or (H, C 1 -C 6 alkoxy) when the double dotted line represents a single bond or when the bond is absent, Y is =O, =NOR 17 (H, H). (H, OH), (H, SH), (H, C 1 -C 6 alkoxy) or (H, substituted-amino); R 22 and R 23 are independently -OH, -OC(O)R 30 , OC(O)NR 30 R 31 , or optionally substituted alkyl, alkenyl, alkynyl, heterocycloalkyl, aryl, cycloalkyl, cycloalkenyl, carbonyl, amino, alkoxy, alkenyloxy, alkynyloxy, heterocycloalkyloxy, cycloalkyloxy, or cycloalkenyloxy; or R 22 and R 10 , or R 23 and R 11 , can form a carbocyclic or heterocyclic ring; and the remaining variables are as described in the specification, Also disclosed are pharmaceutical compositions containing said compounds and their use as thrombin receptor antagonists and blinders to cannabinoid receptors.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式